


01-23-06

JFW

Express Mail Label No. ED 282174108 US  
Date of Deposit: January 20, 2006

Attorney Docket No. CST-214  
PAIR Customer No.: 31012



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: *Wetzel, et al*  
ASSIGNEE: CELL SIGNALING TECHNOLOGY, INC.  
SERIAL NUMBER: 10/807,799 EXAMINER: Not Yet Assigned  
FILING DATE: March 24, 2004 ART UNIT: 1645  
FOR: ANTIBODIES SPECIFIC FOR THE BCR-ABL FUSION PROTEIN AND USES  
THEREOF

January 20, 2006  
Danvers, Massachusetts

Mail Stop AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Attached hereto for filing in the above-identified patent application are the following:

- ☒ Transmittal Letter (w/duplicate) (2 pages);
- ☒ Supplemental Information Disclosure Statement (3 pages);
- ☒ IDS Form – PTO 1449 (w/duplicate) (2 pages);
- ☒ Reference WO 02/069900 A2 (1 reference, CM);
- ☒ Return Postcard.

Respectfully submitted,

James Gregory Cullem, Esq., Reg. No. 43,569  
Intellectual Property Counsel  
Andrew J. Warner, J.D., Reg. No. 56,049  
Patent Agent  
CELL SIGNALING TECHNOLOGY, INC.

Express Mail Label No.: ED 282174108 US

Date of Deposit: January 20, 2006

Attorney Docket No.: CST-214

PAIR Customer No.: 31012



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: *Wetzel, et al*  
ASSIGNEE: CELL SIGNALING TECHNOLOGY, INC.  
SERIAL NUMBER: 10/807,799 EXAMINER: Not Yet Assigned  
FILING DATE: March 24, 2004 ART UNIT: 1645  
FOR: ANTIBODIES SPECIFIC FOR THE BCR-ABL FUSION PROTEIN AND USES THEREOF

January 20, 2006  
Danvers, Massachusetts

Mail Stop AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. The order of presentation of the references should not be construed as an indication of the importance of the references.

**U.S. Patent or Application Documents: None**

**Foreign Patent Documents:**

WO 02/069900 A2 Conforma Therapeutics Corp. 12 September 2002

**Other Prior Art – Non Patent Literature Documents: None**

This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- ☐ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. 37 C.F.R. §1.97.

This Information Disclosure Statement is being filed:

- ☒ after the mailing of a first Office Action on the merits, but before the mailing date of a final Office Action, a Notice of Allowance, or an action that otherwise closes prosecution in the application; and
- ☒ is accompanied by the following statement:
  - ☒ Applicant(s) hereby state(s) that each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement (37 C.F.R. §1.97(e)(1)); or
  - ☐ Applicant(s) hereby state(s) that no item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned representative signing this certification after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in Rule 1.56(c) more than three months prior to the filing of this information disclosure (37 C.F.R. §1.97(e)(2)); and
- ☐ is accompanied by the fee set forth in 37 C.F.R. §1.17(p):
  - ☐ a check for the required fee is enclosed herewith; or
  - ☐ the Commissioner is hereby authorized to charge the required fee (and any other fees that may be due) to U.S. Deposit Account No. 50-1774, Ref. No. CST-207.

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

• APPLICANTS: Wetzel *et al*  
U.S.S.N.: 10/807,799

Attorney Docket No: CST-214


Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-1774, Reference No. CST-214.

Respectfully submitted,



James Gregory Cullem, Esq., Reg. No. 43,569  
Intellectual Property Counsel  
Andrew J. Warner, J.D., Reg. No. 56,049  
CELL SIGNALING TECHNOLOGY, INC.

Dated: January 20, 2006



Express Mail No. ED 282174108 US  
Date of Deposit: January 20, 2006

**BEST AVAILABLE COPY**

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	10/807,799
	<b>Filing Date</b>	March 24, 2004
	<b>First Named Inventor</b>	Wetzel, et al.
	<b>Group Art Unit</b>	1645
	<b>Examiner Name</b>	Not Yet Assigned
	<b>Attorney Docket Number</b>	CST-214

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	CM	WO	02/069900 A2	Conforma Therapeutics Corp.	12 September 2002		NO

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.